Bioimpedance Spectroscopy Preferred for Post-Breast Surgery Lymphedema Risk
By LabMedica International staff writers Posted on 04 Jun 2019 |
Image: Bioimpedance spectroscopy (BIS) is better than a tape measure for assessing a woman’s risk for developing lymphedema after breast cancer surgery, according to interim results of a study (Photo courtesy of Vanderbilt University School of Nursing).
Interim results from a study that compared bioimpedance spectroscopy (BIS) to the classical tape measure for assessing a woman’s risk for developing lymphedema after breast cancer surgery strongly suggested that BIS was the preferred method.
BIS is a painless and relatively simple measurement method. The measured data can be used to determine the amount of fluids in the body as well as estimate body composition. The measurement is based on an assumption that an electric current at low frequencies cannot permeate cells and travels through extra-cellular space only and is used to measure extracellular water (ECW). An electric current at high frequencies permeates cell membranes and is used to measure total body water (TBW).
Breast cancer-related lymphedema (BCRL) represents a major source of morbidity among breast cancer survivors. Lymphedema causes swelling in the arm, can be physically debilitating, and puts women at greater risk for infections as well as psychological stress.
Investigators at Vanderbilt University (Nashville, TN, USA) moderated an international randomized controlled trial comparing lymphedema progression rates using volume measurements calculated from the circumference using a tape measure (TM) or by BIS. The trial included 508 participants who had been monitored for a year or longer. Participants identified at risk for lymphedema received compression sleeves and gauntlets and were instructed to wear them 12 hours daily for 28 days to prevent progression to lymphedema. Patients who developed lymphedema reached their endpoint with the trial and were referred to clinicians for complex decongestive physiotherapy (CDP).
Interim results obtained during the trial demonstrated that post-treatment surveillance with BIS reduced the absolute rates of progression of BCRL requiring CDP by approximately 10%, a clinically meaningful improvement. These results supported the concept of post-treatment surveillance with BIS to detect subclinical BCRL and initiate early intervention.
“The bioimpedance device measures lymphatic fluid, and the tape measures everything,” said senior author Dr. Sheila Ridner, professor of nursing science at Vanderbilt University. “It takes more lymphatic fluid to make your whole arm volume change than it does to make the device pick up changes. The device is just more sensitive to changes in lymphatic fluid.”
“We had statistically significant more people trigger an intervention that were in the tape group than in the BIS group, which was contrary to what many people thought would have happened in the study. One of the concerns about BIS in general was that it might generate false positives and we might psychologically distress people,” said Dr. Ridner. “That was never my experience in the 15 to 16 years I have been working with the technology.”
The interim report was published in the May 3, 2019, online edition of the journal Annals of Surgical Oncology.
Related Links:
Vanderbilt University
BIS is a painless and relatively simple measurement method. The measured data can be used to determine the amount of fluids in the body as well as estimate body composition. The measurement is based on an assumption that an electric current at low frequencies cannot permeate cells and travels through extra-cellular space only and is used to measure extracellular water (ECW). An electric current at high frequencies permeates cell membranes and is used to measure total body water (TBW).
Breast cancer-related lymphedema (BCRL) represents a major source of morbidity among breast cancer survivors. Lymphedema causes swelling in the arm, can be physically debilitating, and puts women at greater risk for infections as well as psychological stress.
Investigators at Vanderbilt University (Nashville, TN, USA) moderated an international randomized controlled trial comparing lymphedema progression rates using volume measurements calculated from the circumference using a tape measure (TM) or by BIS. The trial included 508 participants who had been monitored for a year or longer. Participants identified at risk for lymphedema received compression sleeves and gauntlets and were instructed to wear them 12 hours daily for 28 days to prevent progression to lymphedema. Patients who developed lymphedema reached their endpoint with the trial and were referred to clinicians for complex decongestive physiotherapy (CDP).
Interim results obtained during the trial demonstrated that post-treatment surveillance with BIS reduced the absolute rates of progression of BCRL requiring CDP by approximately 10%, a clinically meaningful improvement. These results supported the concept of post-treatment surveillance with BIS to detect subclinical BCRL and initiate early intervention.
“The bioimpedance device measures lymphatic fluid, and the tape measures everything,” said senior author Dr. Sheila Ridner, professor of nursing science at Vanderbilt University. “It takes more lymphatic fluid to make your whole arm volume change than it does to make the device pick up changes. The device is just more sensitive to changes in lymphatic fluid.”
“We had statistically significant more people trigger an intervention that were in the tape group than in the BIS group, which was contrary to what many people thought would have happened in the study. One of the concerns about BIS in general was that it might generate false positives and we might psychologically distress people,” said Dr. Ridner. “That was never my experience in the 15 to 16 years I have been working with the technology.”
The interim report was published in the May 3, 2019, online edition of the journal Annals of Surgical Oncology.
Related Links:
Vanderbilt University
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines